ESG

Darling Ingredients' new venture with Tessenderlo isn't just a merger; it's a strategic move to dominate the booming collagen and nutrition market.

Nordson's record earnings reveal the high-tech backbone of premium goods and a resilient, behind-the-scenes investment in the high life.

As CEO De Lyle Bloomquist announces his retirement, Rayonier Advanced Materials seeks a new leader to steer its ambitious 'BioFuture' strategy amid market volatility.

Early trial data suggests GRI-0621 could be a game-changer for Idiopathic Pulmonary Fibrosis, showing lung repair and a much better safety profile.

T1 Energy is raising massive capital for its G2_Austin plant and to comply with federal rules, betting big on an American-made clean energy supply chain.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

How a bold $100M pandemic-era investment in a NYC landmark defied market gloom, achieving 100% occupancy and setting a new standard for office resilience.

WelcomeVille Investment Association is launching a platform to fix 'cognitive drift'. Is this the future of professional development or a niche experiment?

A new campaign tackles undiagnosed kidney disease. But is it just public health, or a savvy strategy to reshape a multi-billion dollar market?

Unicharm's new water-saving diaper recycling tech isn't just eco-friendly. It's a bold strategic move to dominate the future of sustainable personal care.

The Army is outsourcing pilot training. A new alliance of industry and academia aims to win the bid, blending operational scale with proven teaching excellence.

As federal aid dwindles, a major health system invests in an innovative food network, betting on infrastructure to combat hunger and chronic disease.

As climate disasters escalate, a major insurer is shifting from payouts to prevention. We decode this signal and its implications for the future of risk.

A new player enters the booming outpatient surgery market. DNV's CMS-approved accreditation challenges rivals with a unique continuous improvement model.

A struggling interactive entertainment firm bets its future on gold, targeting Malaysia's booming market. A look at the high-stakes pivot shaking up BHAT.

With a new patent, this biotech targets the massive orthopedics market. But can its novel fibroblast therapy overcome steep financial and clinical hurdles?

USA Rare Earth is accelerating its timeline to mine critical minerals by two years. Can innovative tech and bold strategy break foreign supply chain dominance?

BlockQuarry unveils a sleek new website for its US-made miner, but can this digital pivot overcome steep financial hurdles and disrupt a crowded market?

Ontario's new FAST program speeds access to cancer drugs like Scemblix, challenging Canada's slow reimbursement system. Is this a new national blueprint?